Spyre Therapeutics (SYRE) Competitors $15.92 -0.95 (-5.66%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYRE vs. ACLX, AKRO, VKTX, MTSR, SWTX, SRRK, MLTX, PTGX, AAPG, and HCMShould you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Arcellx (ACLX), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), Metsera (MTSR), SpringWorks Therapeutics (SWTX), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Spyre Therapeutics vs. Its Competitors Arcellx Akero Therapeutics Viking Therapeutics Metsera SpringWorks Therapeutics Scholar Rock MoonLake Immunotherapeutics Protagonist Therapeutics Ascentage Pharma Group International HUTCHMED Arcellx (NASDAQ:ACLX) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment. Do analysts recommend ACLX or SYRE? Arcellx currently has a consensus target price of $114.31, suggesting a potential upside of 61.23%. Spyre Therapeutics has a consensus target price of $53.40, suggesting a potential upside of 235.51%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spyre Therapeutics is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has more volatility & risk, ACLX or SYRE? Arcellx has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500. Does the media favor ACLX or SYRE? In the previous week, Arcellx had 5 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Arcellx and 7 mentions for Spyre Therapeutics. Arcellx's average media sentiment score of 1.15 beat Spyre Therapeutics' score of 1.12 indicating that Arcellx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ACLX or SYRE more profitable? Spyre Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -211.46%. Arcellx's return on equity of -35.27% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-211.46% -35.27% -22.73% Spyre Therapeutics N/A -77.46%-41.06% Which has better valuation and earnings, ACLX or SYRE? Arcellx has higher revenue and earnings than Spyre Therapeutics. Arcellx is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$107.94M36.20-$107.35M-$2.99-23.71Spyre Therapeutics$890K1,078.00-$208.02M-$3.77-4.22 Do insiders and institutionals hold more shares of ACLX or SYRE? 96.0% of Arcellx shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 8.4% of Arcellx shares are owned by company insiders. Comparatively, 6.2% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryArcellx beats Spyre Therapeutics on 10 of the 16 factors compared between the two stocks. Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRE vs. The Competition Export to ExcelMetricSpyre TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$957.25M$2.96B$5.46B$9.56BDividend YieldN/A2.41%4.71%4.14%P/E Ratio-4.2117.1628.7523.86Price / Sales1,078.00304.89438.0495.35Price / CashN/A42.6035.6858.35Price / Book2.267.958.155.61Net Income-$208.02M-$54.52M$3.25B$265.26M7 Day Performance-7.95%-1.28%-0.97%-1.02%1 Month Performance0.48%13.16%5.25%4.81%1 Year Performance-38.88%11.06%28.36%23.32% Spyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRESpyre Therapeutics2.2524 of 5 stars$15.92-5.7%$53.40+235.5%-35.1%$957.25M$890K-4.2173News CoveragePositive NewsAnalyst ForecastACLXArcellx2.6517 of 5 stars$72.08+1.3%$114.31+58.6%+41.0%$3.92B$76.81M-24.1180News CoveragePositive NewsAnalyst UpgradeAnalyst RevisionAKROAkero Therapeutics4.0571 of 5 stars$48.62+0.5%$81.57+67.8%+108.2%$3.86BN/A-24.9330News CoveragePositive NewsUpcoming EarningsAnalyst ForecastVKTXViking Therapeutics3.9728 of 5 stars$33.98+4.0%$86.92+155.8%-34.6%$3.67BN/A-22.2120MTSRMetseraN/A$34.44-1.3%$55.00+59.7%N/A$3.67BN/A0.0081SWTXSpringWorks Therapeutics0.3797 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230News CoverageSRRKScholar Rock4.3481 of 5 stars$36.99+1.7%$44.14+19.3%+340.8%$3.45B$33.19M-14.62140Earnings ReportGap DownMLTXMoonLake Immunotherapeutics2.7384 of 5 stars$53.32+0.8%$73.14+37.2%+27.9%$3.39BN/A-23.182News CoveragePositive NewsEarnings ReportAnalyst ForecastPTGXProtagonist Therapeutics2.0661 of 5 stars$53.83flat$66.10+22.8%+50.6%$3.34B$434.43M71.77120Positive NewsAAPGAscentage Pharma Group InternationalN/A$37.60+1.1%N/AN/A$3.25B$134.35M0.00600HCMHUTCHMED3.2534 of 5 stars$17.28+0.1%$28.00+62.0%-1.3%$3.01B$630.20M0.001,811Positive NewsUpcoming Earnings Related Companies and Tools Related Companies ACLX Competitors AKRO Competitors VKTX Competitors MTSR Competitors SWTX Competitors SRRK Competitors MLTX Competitors PTGX Competitors AAPG Competitors HCM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRE) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRE Stock Alerts